HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

JIUYUAN GENE

5.400

+0.2855.57%

Volume:23.00K

Turnover:121.95K

Market Cap:1.30B

PE:8.19

High:5.400

Open:5.275

Low:5.230

Close:5.115

52wk High:13.071

52wk Low:4.600

Shares:240.00M

HK Float Shares:240.00M

Volume Ratio:1.94

T/O Rate:0.01%

Dividend:0.07

Dividend Rate:1.23%

EPS(LYR):0.660

ROE:8.50%

ROA:4.52%

PB:0.66

PE(LYR):8.19

PS:0.85

Loading ...

Overview Company News Filings

九源基因2025年营收同比降4.59%至人民币13.063亿元，聚焦创新驱动与全球化战略

Bulletin Express

Jiuyuan Gene Updates Market on Public Float Restoration; Expects Compliance by Q2 2026

Bulletin Express

JIUYUAN GENE (02566) Completes Filing with CSRC for H-Share Full Circulation Plan

JIUYUAN GENE Receives CSRC Filing Notice for 136.30 Million-Share H Share Full Circulation

Bulletin Express

Hangzhou Jiuyuan Gene says CSRC clears H-share full circulation filing for 136.3 million shares

Stable 10.6% Margin At Hangzhou Jiuyuan Genetic Biopharmaceutical Reinforces Bullish Valuation Narratives

Simply Wall St.

Stock Track | JIUYUAN GENE Plummets 5.08% Intraday on Weak FY25 Results with Revenue Decline

JIUYUAN GENE (02566) Proposes Appointment of Dr. Huang Wenli as Independent Non-Executive Director

JIUYUAN GENE (02566) Announces Annual Results: Profit Attributable to Owners Reaches RMB 138 Million, Proposes Final Dividend of RMB 0.57 per 10 Shares

Jiuyuan Gene Updates Board Governance Framework with Revised Nomination Committee Charter Effective March 2026

Bulletin Express

Hangzhou Jiuyuan Gene proposes final dividend of RMB 0.57 per 10 shares

Hangzhou Jiuyuan FY25 revenue falls 4.6% to RMB 1.3 billion

Jiuyuan Gene targets 31.13% public float through 136.30 million-share H-share conversion

Bulletin Express

Hangzhou Jiuyuan Gene Engineering; public float rises to about 31.13% due to planned H-share full circulation pending CSRC filing notice by end-April 2026

JIUYUAN GENE Withdraws 2026 Share Award Scheme Resolutions and Cancels 8 Apr Extraordinary General Meeting

Bulletin Express

Jiuyuan Gene (02566.HK) Sets 30 Mar 2026 Board Meeting for FY2025 Results and Dividend Review

Bulletin Express

Hangzhou Jiuyuan Genetic Biopharmaceutical to hold board meeting on 2025 audited results and final dividend proposal

JIUYUAN GENE's JY47 Injection Receives Implied Clinical Trial Approval from NMPA

Jiuyuan Gene (02566) Secures NMPA IND Approval for SIRPα-Targeting JY47 Injection in MASH with Liver Fibrosis

Bulletin Express

Hangzhou Jiuyuan Gene Engineering wins NMPA clinical trial approval for JY47 injection IND

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/02566/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02566","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02566\",,,,,undefined,":{"symbol":"02566","market":"HK","secType":"STK","nameCN":"JIUYUAN GENE","latestPrice":5.4,"timestamp":1789114134063,"preClose":5.115,"halted":0,"volume":23000,"delay":0,"changeRate":0.05571847507331381,"floatShares":240000000,"shares":240000000,"eps":0.6596418693148836,"marketStatus":"Market Closed","change":0.285,"latestTime":"09-11 16:08:54","open":5.275,"high":5.4,"low":5.23,"amount":121945,"amplitude":0.033236,"askPrice":5.495,"askSize":200,"bidPrice":5.295,"bidSize":3600,"shortable":0,"etf":0,"ttmEps":0.6696802130339968,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":7,"adr":0,"listingDate":1732723200000,"exchange":"SEHK","adjPreClose":5.115,"dividendRate":0.012285,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":1.9425675610048392,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02566\",,,,,undefined,":{"symbol":"02566","floatShares":240000000,"roa":"4.52%","roe":"8.50%","lyrEps":0.659642,"volumeRatio":1.9425675610048392,"shares":240000000,"dividePrice":0.066665,"high":5.4,"amplitude":0.033236,"preClose":5.115,"low":5.23,"week52Low":4.6,"pbRate":"0.66","psRate":"0.85","week52High":13.071,"institutionHeld":0,"latestPrice":5.4,"committee":0.894737,"eps":0.6596418693148836,"divideRate":0.012345,"volume":23000,"delay":0,"ttmEps":0.6696802130339968,"open":5.275,"prevYearClose":7.475,"prevWeekClose":5.25,"prevMonthClose":5.4,"prevQuarterClose":5.9,"fiveDayClose":5.25,"twentyDayClose":5.41,"sixtyDayClose":5.72,"dividendFrequency":"A","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.008171466845277964},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02566\",params:#limit:5,,,undefined,":[{"date":"2026-08-19","symbol":"02566","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787103000000,"name":null,"time":"","dateTimestamp":1787068800000,"actualEps":null},{"date":"2026-06-17","symbol":"02566","amount":0.057,"announcedDate":"2026-03-30","type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2026-06-18","defaultRemindTime":1781659800000,"name":"九源基因","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-30","payableDate":"2026-06-18","currency":"CNY","dateTimestamp":1781625600000,"payDate":"2026-07-30"},{"date":"2026-03-30","symbol":"02566","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null},{"date":"2025-08-18","symbol":"02566","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755480600000,"name":null,"time":"","dateTimestamp":1755446400000,"actualEps":null},{"date":"2025-06-13","symbol":"02566","amount":0.056,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2025-06-16","defaultRemindTime":1749778200000,"name":"九源基因","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-30","payableDate":"2025-06-16","currency":"CNY","dateTimestamp":1749744000000,"payDate":"2025-07-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02566\",market:\"HK\",,,undefined,":[{"executeDate":"2025-06-13","recordDate":"2025-06-16","paymentDate":"2025-07-30","value":0.056,"currency":"CNY"},{"executeDate":"2026-06-17","recordDate":"2026-06-18","paymentDate":"2026-07-30","value":0.057,"currency":"CNY"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02566\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02566\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02566","date":"2026-09-11","current":8.063677,"percent":0.055172,"low":7.540023,"twenty":9.887871,"median":12.500478,"eighty":16.568623,"high":28.852596,"avg":13.33281,"sd":4.407027,"marketCap":1299446280},"quantilePoints":[{"date":"2024-12-06","current":14.097915,"twenty":14.208262,"median":14.275695,"eighty":14.595644,"marketCap":1946012484},{"date":"2024-12-13","current":13.217326,"twenty":13.348436,"median":13.95821,"eighty":14.334483,"marketCap":1820859096},{"date":"2024-12-20","current":12.20261,"twenty":12.40882,"median":13.381214,"eighty":14.243818,"marketCap":1673619816},{"date":"2024-12-27","current":12.158366,"twenty":12.254449,"median":13.1954,"eighty":14.180675,"marketCap":1666257852},{"date":"2025-01-03","current":11.126814,"twenty":12.0799,"median":12.46117,"eighty":14.042033,"marketCap":1526380536},{"date":"2025-01-10","current":9.714633,"twenty":11.141125,"median":12.29741,"eighty":13.763077,"marketCap":1327607508},{"date":"2025-01-17","current":9.904165,"twenty":10.518129,"median":12.180488,"eighty":13.509332,"marketCap":1354601376},{"date":"2025-01-24","current":10.07429,"twenty":9.9409,"median":12.04207,"eighty":13.348436,"marketCap":1386503220},{"date":"2025-01-28","current":10.358786,"twenty":9.995541,"median":11.819979,"eighty":13.282881,"marketCap":1433128992},{"date":"2025-02-07","current":11.238302,"twenty":10.0243,"median":11.162591,"eighty":13.191014,"marketCap":1546012440},{"date":"2025-02-14","current":11.154484,"twenty":10.062805,"median":11.126814,"eighty":12.776093,"marketCap":1533742500},{"date":"2025-02-21","current":12.73316,"twenty":10.073062,"median":11.193598,"eighty":12.735779,"marketCap":1757055408},{"date":"2025-02-28","current":11.508443,"twenty":10.189099,"median":11.508443,"eighty":12.653552,"marketCap":1582822260},{"date":"2025-03-07","current":12.084413,"twenty":10.276651,"median":11.554796,"eighty":12.584056,"marketCap":1668711840},{"date":"2025-03-14","current":12.91496,"twenty":10.28916,"median":11.611229,"eighty":12.584056,"marketCap":1784049276},{"date":"2025-03-21","current":12.244709,"twenty":10.311241,"median":11.810026,"eighty":12.735779,"marketCap":1690797732},{"date":"2025-03-28","current":11.696332,"twenty":10.344738,"median":11.831112,"eighty":12.72799,"marketCap":1734969516},{"date":"2025-04-03","current":10.807781,"twenty":10.395616,"median":11.800074,"eighty":12.674918,"marketCap":1600000176},{"date":"2025-04-11","current":9.828764,"twenty":10.27298,"median":11.65378,"eighty":12.589531,"marketCap":1445398932},{"date":"2025-04-17","current":9.988361,"twenty":10.075173,"median":11.569961,"eighty":12.56072,"marketCap":1472392800},{"date":"2025-04-25","current":10.079541,"twenty":10.050182,"median":11.463659,"eighty":12.511173,"marketCap":1487116728},{"date":"2025-05-02","current":10.290636,"twenty":10.067013,"median":11.287756,"eighty":12.494061,"marketCap":1467484824},{"date":"2025-05-09","current":10.406872,"twenty":10.062805,"median":11.203375,"eighty":12.472285,"marketCap":1494478692},{"date":"2025-05-16","current":10.339488,"twenty":10.073062,"median":11.154484,"eighty":12.457737,"marketCap":1496932680},{"date":"2025-05-23","current":10.443848,"twenty":10.076938,"median":11.100884,"eighty":12.429027,"marketCap":1516564584},{"date":"2025-05-30","current":10.499086,"twenty":10.079206,"median":11.063697,"eighty":12.408842,"marketCap":1531288512},{"date":"2025-06-06","current":10.405237,"twenty":10.102813,"median":10.92653,"eighty":12.402573,"marketCap":1521472560},{"date":"2025-06-13","current":16.776007,"twenty":10.127345,"median":11.063697,"eighty":12.429027,"marketCap":2453988000},{"date":"2025-06-20","current":13.783342,"twenty":10.148232,"median":11.100884,"eighty":12.535947,"marketCap":2012270160},{"date":"2025-06-27","current":13.241991,"twenty":10.175286,"median":11.154484,"eighty":12.72799,"marketCap":1938650520},{"date":"2025-07-04","current":14.247042,"twenty":10.191457,"median":11.198369,"eighty":12.80722,"marketCap":2085889800},{"date":"2025-07-11","current":16.12378,"twenty":10.199228,"median":11.287756,"eighty":13.164345,"marketCap":2358282468},{"date":"2025-07-18","current":16.959198,"twenty":10.204599,"median":11.508443,"eighty":13.325525,"marketCap":2478527880},{"date":"2025-07-25","current":16.429296,"twenty":10.22327,"median":11.606189,"eighty":13.872228,"marketCap":2409816216},{"date":"2025-08-01","current":16.329429,"twenty":10.25109,"median":11.703755,"eighty":14.068336,"marketCap":2380368360},{"date":"2025-08-08","current":17.296232,"twenty":10.27298,"median":11.825546,"eighty":14.242565,"marketCap":2527607640},{"date":"2025-08-15","current":25.546022,"twenty":10.28665,"median":12.04207,"eighty":14.454008,"marketCap":3727607772},{"date":"2025-08-22","current":27.152477,"twenty":10.291424,"median":12.068084,"eighty":15.48419,"marketCap":3646626168},{"date":"2025-08-29","current":24.186548,"twenty":10.297713,"median":12.158366,"eighty":16.326447,"marketCap":3263804040},{"date":"2025-09-05","current":26.17651,"twenty":10.31224,"median":12.214209,"eighty":16.547432,"marketCap":3528834744},{"date":"2025-09-12","current":23.22216,"twenty":10.322989,"median":12.270192,"eighty":16.690567,"marketCap":3136196664},{"date":"2025-09-19","current":21.82033,"twenty":10.32445,"median":12.326094,"eighty":16.958366,"marketCap":2944785600},{"date":"2025-09-26","current":20.564467,"twenty":10.331172,"median":12.407292,"eighty":17.223519,"marketCap":2768098464},{"date":"2025-10-03","current":22.006879,"twenty":10.341379,"median":12.455816,"eighty":17.606421,"marketCap":2969325480},{"date":"2025-10-10","current":19.015463,"twenty":10.348945,"median":12.489783,"eighty":18.310381,"marketCap":2561963472},{"date":"2025-10-17","current":16.970486,"twenty":10.358786,"median":12.586793,"eighty":18.134776,"marketCap":2284662828},{"date":"2025-10-24","current":16.253675,"twenty":10.405237,"median":12.724544,"eighty":17.900127,"marketCap":2188957296},{"date":"2025-10-31","current":15.392522,"twenty":10.406545,"median":12.739707,"eighty":17.871014,"marketCap":2076073848},{"date":"2025-11-07","current":13.654382,"twenty":10.406872,"median":12.862233,"eighty":17.830642,"marketCap":1840491000},{"date":"2025-11-14","current":13.652109,"twenty":10.414705,"median":13.150654,"eighty":17.669327,"marketCap":1845398976},{"date":"2025-11-21","current":13.022772,"twenty":10.429703,"median":12.977364,"eighty":17.532486,"marketCap":1759509396},{"date":"2025-11-28","current":14.151953,"twenty":10.441671,"median":13.150654,"eighty":17.476552,"marketCap":1919018616},{"date":"2025-12-05","current":15.0671,"twenty":10.446315,"median":13.212896,"eighty":17.360095,"marketCap":2046625992},{"date":"2025-12-12","current":15.021249,"twenty":10.450076,"median":13.373682,"eighty":17.303573,"marketCap":2044172004},{"date":"2025-12-19","current":13.906512,"twenty":10.4562,"median":13.596735,"eighty":17.18567,"marketCap":1896932724},{"date":"2025-12-24","current":13.468772,"twenty":10.460694,"median":13.541362,"eighty":17.140598,"marketCap":1842944988},{"date":"2026-01-02","current":13.594612,"twenty":10.472165,"median":13.526709,"eighty":17.103787,"marketCap":1867484868},{"date":"2026-01-09","current":14.184539,"twenty":10.508332,"median":13.623361,"eighty":17.043007,"marketCap":1953374448},{"date":"2026-01-16","current":15.82386,"twenty":10.552044,"median":13.654647,"eighty":16.970089,"marketCap":2186209278},{"date":"2026-01-23","current":17.221546,"twenty":10.59039,"median":13.760784,"eighty":17.043007,"marketCap":2377029620},{"date":"2026-01-30","current":18.645413,"twenty":10.66635,"median":13.818506,"eighty":17.208843,"marketCap":2585326030},{"date":"2026-02-06","current":17.570145,"twenty":10.791312,"median":13.890789,"eighty":17.500019,"marketCap":2442411318},{"date":"2026-02-13","current":16.566637,"twenty":10.808038,"median":13.930604,"eighty":17.447639,"marketCap":2316142276},{"date":"2026-02-20","current":15.898541,"twenty":10.808553,"median":13.936612,"eighty":17.405456,"marketCap":2219535716},{"date":"2026-02-27","current":15.400942,"twenty":10.876548,"median":13.991046,"eighty":17.345071,"marketCap":2173647600},{"date":"2026-03-06","current":14.146009,"twenty":10.927529,"median":14.014987,"eighty":17.323365,"marketCap":1980434480},{"date":"2026-03-13","current":13.445786,"twenty":10.970802,"median":13.989227,"eighty":17.304533,"marketCap":1891073412},{"date":"2026-03-20","current":14.324288,"twenty":11.037013,"median":13.985049,"eighty":17.25142,"marketCap":2007001284},{"date":"2026-03-27","current":13.721414,"twenty":11.063706,"median":13.970301,"eighty":17.198531,"marketCap":1917640216},{"date":"2026-04-02","current":10.613398,"twenty":11.02367,"median":13.933608,"eighty":17.173124,"marketCap":1671293488},{"date":"2026-04-10","current":10.730025,"twenty":10.921534,"median":13.908042,"eighty":17.15803,"marketCap":1702690620},{"date":"2026-04-17","current":10.908083,"twenty":10.807781,"median":13.879703,"eighty":17.114449,"marketCap":1731672588},{"date":"2026-04-24","current":10.496724,"twenty":10.72787,"median":13.842971,"eighty":17.099223,"marketCap":1666463160},{"date":"2026-04-30","current":10.935086,"twenty":10.702023,"median":13.783342,"eighty":17.068754,"marketCap":1736502916},{"date":"2026-05-08","current":10.594139,"twenty":10.67921,"median":13.733566,"eighty":16.988616,"marketCap":1688199636},{"date":"2026-05-15","current":10.339602,"twenty":10.612541,"median":13.678484,"eighty":16.968896,"marketCap":1651972176},{"date":"2026-05-22","current":9.81785,"twenty":10.57772,"median":13.654515,"eighty":16.961058,"marketCap":1565026272},{"date":"2026-05-29","current":9.044003,"twenty":10.498141,"median":13.649387,"eighty":16.95795,"marketCap":1446683236},{"date":"2026-06-05","current":8.457984,"twenty":10.457266,"median":13.565546,"eighty":16.950392,"marketCap":1354907004},{"date":"2026-06-12","current":7.84515,"twenty":10.439494,"median":13.517899,"eighty":16.945188,"marketCap":1255885280},{"date":"2026-06-18","current":9.015379,"twenty":10.406872,"median":13.501167,"eighty":16.890943,"marketCap":1446683236},{"date":"2026-06-26","current":8.75713,"twenty":10.374116,"median":13.445786,"eighty":16.79658,"marketCap":1398379956},{"date":"2026-07-03","current":9.944532,"twenty":10.341471,"median":13.381214,"eighty":16.771208,"marketCap":1589177912},{"date":"2026-07-10","current":9.593587,"twenty":10.324058,"median":13.25487,"eighty":16.748323,"marketCap":1531213976},{"date":"2026-07-17","current":9.016752,"twenty":10.293006,"median":13.217326,"eighty":16.724074,"marketCap":1444268072},{"date":"2026-07-24","current":7.64292,"twenty":10.258532,"median":13.162063,"eighty":16.679208,"marketCap":1224488148},{"date":"2026-07-31","current":8.064769,"twenty":10.200205,"median":13.05573,"eighty":16.651478,"marketCap":1294527904},{"date":"2026-08-07","current":7.771324,"twenty":10.158149,"median":12.918657,"eighty":16.626081,"marketCap":1249847370},{"date":"2026-08-14","current":8.113953,"twenty":10.118328,"median":12.875119,"eighty":16.619851,"marketCap":1306603724},{"date":"2026-08-21","current":7.572239,"twenty":10.071221,"median":12.803792,"eighty":16.5966,"marketCap":1231733640},{"date":"2026-08-28","current":7.91275,"twenty":10.004985,"median":12.728852,"eighty":16.594582,"marketCap":1287414370},{"date":"2026-09-04","current":7.761732,"twenty":9.969361,"median":12.60048,"eighty":16.584855,"marketCap":1263350550},{"date":"2026-09-11","current":7.972736,"twenty":9.887871,"median":12.500478,"eighty":16.568623,"marketCap":1299446280}],"updateTime":1789179420681},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02566\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1171556606","title":"九源基因2025年营收同比降4.59%至人民币13.063亿元，聚焦创新驱动与全球化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1171556606","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171556606?lang=en_us&edition=fundamental","pubTime":"2026-04-23 17:15","pubTimestamp":1776935703,"startTime":"0","endTime":"0","summary":"九源基因（02566）公布2025年度业绩报告，全年实现营业收入人民币13.063亿元（2024年为人民币13.692亿元），同比下降4.59%。尽管营收有所下滑，企业依然保持了稳健的盈利能力，实现净利润人民币1.384亿元，与上年基本持平。公司全年毛利为人民币10.541亿元，毛利率由上年的79.00%提升至80.69%，主要得益于成本管控与生产效率的改善。...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"九源基因2025年营收同比降4.59%至人民币13.063亿元，聚焦创新驱动与全球化战略","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138236039","title":"Jiuyuan Gene Updates Market on Public Float Restoration; Expects Compliance by Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1138236039","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138236039?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:23","pubTimestamp":1775640182,"startTime":"0","endTime":"0","summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) released its latest monthly update, confirming that public float remains at 22.22%, below the minimum threshold stipulated under...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176211726","title":"JIUYUAN GENE (02566) Completes Filing with CSRC for H-Share Full Circulation Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1176211726","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176211726?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:30","pubTimestamp":1775136617,"startTime":"0","endTime":"0","summary":"JIUYUAN GENE (02566) announced that on April 2, 2026, the China Securities Regulatory Commission (CSRC) issued a filing notice to the company regarding its H-share full circulation plan. According to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158125386","title":"JIUYUAN GENE Receives CSRC Filing Notice for 136.30 Million-Share H Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1158125386","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158125386?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:26","pubTimestamp":1775136361,"startTime":"0","endTime":"0","summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (JIUYUAN GENE) announced that the China Securities Regulatory Commission (CSRC) issued a filing notice on 2 April 2026 approving the company’s H...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624250432","title":"Hangzhou Jiuyuan Gene says CSRC clears H-share full circulation filing for 136.3 million shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624250432","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624250432?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:15","pubTimestamp":1775135722,"startTime":"0","endTime":"0","summary":"Hangzhou Jiuyuan Gene Engineering received a filing notice on April 2, 2026 covering its H-share full circulation plan.Filing completed for conversion of 136,302,015 unlisted shares held by 12 shareholders into H shares.Conversion must be completed within 12 months of filing notice date or filing materials must be updated to continue process.Next step targets application to Hong Kong Stock Exchange for listing and dealing permission for converted H shares.Implementation plan remains unfinished, with further updates expected as process advances.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Jiuyuan Gene Engineering Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLb0jnN1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624548043","title":"Stable 10.6% Margin At Hangzhou Jiuyuan Genetic Biopharmaceutical Reinforces Bullish Valuation Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2624548043","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624548043?lang=en_us&edition=fundamental","pubTime":"2026-04-01 21:28","pubTimestamp":1775050139,"startTime":"0","endTime":"0","summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical (SEHK:2566) has put fresh FY 2025 numbers on the table, with first half revenue of C¥638.8 million and basic EPS of C¥0.37 setting the tone for how the year is shaping up. Over recent halves the company has seen revenue move from C¥702.4 million and EPS of C¥0.53 in 1H 2024 to C¥666.8 million and EPS of C¥0.16 in 2H 2024, giving investors a clear view of how the current run rate compares with recent history. With trailing 12 month net profit margins...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2566/hangzhou-jiuyuan-genetic-biopharmaceutical-shares/news/stable-106-margin-at-hangzhou-jiuyuan-genetic-biopharmaceuti","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2566/hangzhou-jiuyuan-genetic-biopharmaceutical-shares/news/stable-106-margin-at-hangzhou-jiuyuan-genetic-biopharmaceuti","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BLSX","BLSG","02566","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153677162","title":"Stock Track | JIUYUAN GENE Plummets 5.08% Intraday on Weak FY25 Results with Revenue Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=1153677162","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153677162?lang=en_us&edition=fundamental","pubTime":"2026-03-31 10:06","pubTimestamp":1774922812,"startTime":"0","endTime":"0","summary":"JIUYUAN GENE's stock plummeted 5.08% during intraday trading on Tuesday, following the release of its full-year 2025 financial results which showed a decline in revenue.The company reported that...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111368780","title":"JIUYUAN GENE (02566) Proposes Appointment of Dr. Huang Wenli as Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1111368780","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111368780?lang=en_us&edition=fundamental","pubTime":"2026-03-31 01:26","pubTimestamp":1774891577,"startTime":"0","endTime":"0","summary":"JIUYUAN GENE (02566) announced that the board of directors has proposed the appointment of Dr. Huang Wenli as an independent non-executive director. The proposed appointment is set to take effect...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146619556","title":"JIUYUAN GENE (02566) Announces Annual Results: Profit Attributable to Owners Reaches RMB 138 Million, Proposes Final Dividend of RMB 0.57 per 10 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1146619556","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146619556?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:26","pubTimestamp":1774884380,"startTime":"0","endTime":"0","summary":"JIUYUAN GENE (02566) has released its annual results for the period ended December 31, 2025. The group reported revenue of RMB 1.306 billion. Profit attributable to owners for the year was RMB 138...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566","BK4585","BK1161","VIG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145577533","title":"Jiuyuan Gene Updates Board Governance Framework with Revised Nomination Committee Charter Effective March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1145577533","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145577533?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:07","pubTimestamp":1774883266,"startTime":"0","endTime":"0","summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (“Jiuyuan Gene”, 02566) has released an updated “Terms of Reference of the Nomination Committee of the Board of Directors,” which will take effect...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623467813","title":"Hangzhou Jiuyuan Gene proposes final dividend of RMB 0.57 per 10 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2623467813","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623467813?lang=en_us&edition=fundamental","pubTime":"2026-03-30 22:18","pubTimestamp":1774880289,"startTime":"0","endTime":"0","summary":"Hangzhou Jiuyuan Gene Engineering proposed final dividend for year ended Dec. 31, 2025 of RMB 0.57 per 10 shares.Shareholders set to vote on proposal on June 15, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Jiuyuan Gene Engineering Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDLrt0jc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623346499","title":"Hangzhou Jiuyuan FY25 revenue falls 4.6% to RMB 1.3 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2623346499","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623346499?lang=en_us&edition=fundamental","pubTime":"2026-03-30 22:12","pubTimestamp":1774879934,"startTime":"0","endTime":"0","summary":"Hangzhou Jiuyuan Gene reported 2025 profit attributable to owners of RMB 138 million, little changed from a year earlier.Revenue slipped 4.6% to RMB 1.3 billion, driven mainly by lower orthopedic product sales amid DRGs/DIP reforms and online listing-related price cuts.Gross margin widened 1.7 percentage points to 80.7% on lower raw material costs and lean production management.Two new products launched in 2025: Jixinfen generated RMB 11 million in sales, while Jilixin contributed RMB 2 million.For 2026, strategy targets a portfolio centered on innovative drugs and biopharmaceutical-device combinations, with metabolic pipelines including JY54  and JY54-2 .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Jiuyuan Gene Engineering","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL6FQgmc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162272003","title":"Jiuyuan Gene targets 31.13% public float through 136.30 million-share H-share conversion","url":"https://stock-news.laohu8.com/highlight/detail?id=1162272003","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162272003?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:40","pubTimestamp":1774428048,"startTime":"0","endTime":"0","summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) has detailed a concrete timetable to resolve its public-float shortfall by converting 136.30 million unlisted domestic shares held...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622025777","title":"Hangzhou Jiuyuan Gene Engineering; public float rises to about 31.13% due to planned H-share full circulation pending CSRC filing notice by end-April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622025777","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622025777?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:39","pubTimestamp":1774427993,"startTime":"0","endTime":"0","summary":"Hangzhou Jiuyuan Gene Engineering; public float rises to about 31.13% due to planned H-share full circulation pending CSRC filing notice by end-April 2026. Hangzhou Jiuyuan Genetic Biopharmaceutical said it expects to receive a filing notice from the China Securities Regulatory Commission by end-April 2026 for its H-share full circulation plan.The proposal would convert 136.3 million unlisted shares held by 12 shareholders into H shares, lifting public float to about 31.13% and restoring compliance with the minimum prescribed percentage.After the filing notice, the company plans to complete required procedures in 2Q2026, subject to regulatory reviews and approvals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Jiuyuan Gene En","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL34tnvd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164747939","title":"JIUYUAN GENE Withdraws 2026 Share Award Scheme Resolutions and Cancels 8 Apr Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1164747939","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164747939?lang=en_us&edition=fundamental","pubTime":"2026-03-25 12:21","pubTimestamp":1774412486,"startTime":"0","endTime":"0","summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (JIUYUAN GENE) announced on 25 March 2026 that its board has withdrawn all resolutions related to the proposed 2026 Share Award Scheme. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186435048","title":"Jiuyuan Gene (02566.HK) Sets 30 Mar 2026 Board Meeting for FY2025 Results and Dividend Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1186435048","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186435048?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:21","pubTimestamp":1773829312,"startTime":"0","endTime":"0","summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene, 02566.HK) has scheduled a board meeting for Monday, 30 March 2026. The agenda comprises:   1. Reviewing and approving the audited...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620234980","title":"Hangzhou Jiuyuan Genetic Biopharmaceutical to hold board meeting on 2025 audited results and final dividend proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2620234980","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620234980?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:15","pubTimestamp":1773828911,"startTime":"0","endTime":"0","summary":"Jiuyuan Gene said its board will meet on March 30, 2026 to consider and approve the audited results for the year ended Dec. 31, 2025. The board will also consider a recommendation on a final dividend at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Jiuyuan Gene Engineering Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLbFrSdh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128209026","title":"JIUYUAN GENE's JY47 Injection Receives Implied Clinical Trial Approval from NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1128209026","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128209026?lang=en_us&edition=fundamental","pubTime":"2026-03-17 17:26","pubTimestamp":1773739577,"startTime":"0","endTime":"0","summary":"JIUYUAN GENE (02566) has announced that the Investigational New Drug (IND) application for its independently developed JY47 injection has received implied approval for clinical trials from China's...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181125783","title":"Jiuyuan Gene (02566) Secures NMPA IND Approval for SIRPα-Targeting JY47 Injection in MASH with Liver Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=1181125783","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181125783?lang=en_us&edition=fundamental","pubTime":"2026-03-17 17:23","pubTimestamp":1773739385,"startTime":"0","endTime":"0","summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene, 02566) disclosed that China’s National Medical Products Administration (NMPA) has cleared the Company’s investigational new drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620405974","title":"Hangzhou Jiuyuan Gene Engineering wins NMPA clinical trial approval for JY47 injection IND","url":"https://stock-news.laohu8.com/highlight/detail?id=2620405974","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620405974?lang=en_us&edition=fundamental","pubTime":"2026-03-17 17:19","pubTimestamp":1773739190,"startTime":"0","endTime":"0","summary":"Hangzhou Jiuyuan Gene said China’s National Medical Products Administration granted clinical trial approval for its JY47 Injection under an investigational new drug application. The monoclonal antibody targets SIRPα and is intended for metabolic dysfunction-associated steatohepatitis with liver fibrosis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Jiuyuan Gene Engineering Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL29jTnK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02566"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":81,"code":"91000000","status":"200"}]}}